Glioblastoma News and Research

RSS

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

ImmunoCellular signs licensing agreement with Caltech to develop antigen-specific T-cell technology

ImmunoCellular Therapeutics, Ltd. announced today that it has established a licensing agreement with the California Institute of Technology for exclusive rights to novel technology for the development of certain antigen specific T-cell immunotherapies for the treatment of cancer.

24 Sep 2014

Broach Foundation makes $5 million commitment to support glioblastoma multiforme research

The Broach Foundation for Brain Cancer Research has made a $5 million commitment to support glioblastoma multiforme research at The University of Texas MD Anderson Cancer Center.

15 Sep 2014

Using handheld Raman scanner researchers completely removed brain tumors

Cancerous brain tumors are notorious for growing back despite surgical attempts to remove them - and for leading to a dire prognosis for patients.

4 Sep 2014

One-two punch designed to knock out most dangerous brain cancer

University of Michigan Health System doctors have started testing a unique new approach to fighting brain tumors -- one that delivers a one-two punch designed to knock out the most dangerous brain cancer.

3 Sep 2014

TGen to lead first-in-patient clinical trial studies to test novel drugs for glioblastoma

SIn 2012, The Ben & Catherine Ivy Foundation awarded $10 million in grants for two groundbreaking brain cancer research projects at the Translational Genomics Research Institute. One of those projects has officially received the final regulatory approval from University of California, San Francisco, which means patient enrollment for the trial can begin.

29 Aug 2014

Researchers find why certain glioblastomas become drug resistance

Researchers at the University of California, San Diego School of Medicine have found one of the keys to why certain glioblastomas - the primary form of a deadly brain cancer - are resistant to drug therapy.

26 Aug 2014

Researchers find more selective therapies for cancer

Thanks to important discoveries in basic and clinical research and technological advances, the fight against cancer has mobilized into a complex offensive spanning multiple fronts.

25 Aug 2014

Research validates Myc inhibition as effective therapeutic strategy for glioma

Research led by the Vall d'Hebron Institute of Oncology (VHIO) evidence the most conclusive preclinical results to-date validating Myc inhibition as a therapeutic strategy in glioma - a highly agressive tumor type that notoriously outsmarts current anti-cancer therapies.

19 Aug 2014

Novogen declares shareholder meeting results

Australia-US biotechnology company, Novogen Ltd., an oncology and degenerative diseases drug development company, today announced the results of its General Meeting of Shareholders, which was held on August 12 in Sydney, Australia.

13 Aug 2014

Identifying epigenetic markers in cancer cells could improve patient treatment

Scientists have known for decades that cancer can be caused by genetic mutations, but more recently they have discovered that chemical modifications of a gene can also contribute to cancer.

13 Aug 2014

Study: Brain tumors hijack the brain's existing blood supply during progression

Dangerous brain tumors hijack the brain's existing blood supply throughout their progression, by growing only within narrow potential spaces between and along the brain's thousands of small blood vessels, new research shows for the first time.

12 Aug 2014

OncoSynergy's OS2966 receives FDA orphan drug designation for treatment of glioblastoma

OncoSynergy announced today that the FDA Office of Orphan Products Development has granted orphan drug designation for the investigational drug candidate OS2966, a neutralizing anti-CD29 monoclonal antibody, for the treatment of glioblastoma, the most common and deadliest primary adult brain tumor.

12 Aug 2014

Novogen receives funding support to commence studies in muscular dystrophy

The Australian biotechnology company, Novogen Limited today announced receipt of funding from the FSHD Global Research Foundation as part of the Company’s efforts to find effective treatments for a range of musculo-degenerative diseases including facioscapulohumeral dystrophy (FSHD).

11 Aug 2014

Celsion announces financial results for second quarter ended 2014

Celsion Corporation, an oncology drug development company, today announced financial results for the second quarter ended June 30, 2014.

7 Aug 2014

Findings show how galectin-1 protein plays key role in high grade malignant gliomas

Brain tumors fly under the radar of the body's defense forces by coating their cells with extra amounts of a specific protein, new research shows.

7 Aug 2014

Induced immunorejection may eliminate tumors post-cell transplantation

Recent studies have shown that transplanting induced pluripotent stem cell-derived neural stem cells (iPS-NSCs) can promote functional recovery after spinal cord injury in rodents and non-human primates. However, a serious drawback to the transplantation of iPS-NSCs is the potential for tumor growth, or tumorogenesis, post-transplantation.

7 Aug 2014

Triple therapy for glioblastoma has prolonged survival of mice with brain cancers

A triple therapy for glioblastoma, including two types of immunotherapy and targeted radiation, has significantly prolonged the survival of mice with these brain cancers, according to a new report by scientists at the Johns Hopkins Kimmel Cancer Center.

5 Aug 2014